Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

DarioHealth Corp. Common Stock

DRIO

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.13 – $1.37
Volume 33,166
Market cap $13M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$12.98M
Price / earnings
0×
Price / book
0.18×
Price / sales
0.61×
EV / sales
0.77×
EV / EBITDA
-0.58×

Profitability

Earnings per share
$727.91
Return on assets
7,307.51%
Return on equity
11,528.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.44×
Current ratio
4.2×
Quick ratio
3.81×
Cash ratio
3.04×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DRIO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$5.31M$5.18M$5.58M$5.23M$5.01M$5.37M$6.75M$7.6M
Cost of revenue$2.17M$1.99M$2.38M$2.43M$1.99M$2.41M$2.87M$3.4M
Gross profit$3.15M$3.19M$3.2M$2.8M$3.02M$2.96M$3.88M$4.2M
Selling, general and administrative$8.9M$7.57M$8.12M$8.73M$9.17M$8.44M$9.18M$10.59M
Research and development$2.3M$2.1M$2.39M$2.63M$3.33M$3.72M$4.11M$5.28M
Total operating expenses$11.19M$9.67M$10.51M$11.37M$12.5M$12.16M$13.29M$15.87M
Operating income-$8.05M-$6.48M-$7.31M-$8.56M-$9.48M-$9.2M-$9.41M-$11.67M
Interest expense-$1.09M-$1.12M-$1.15M-$1.1M-$1.16M$0$0$0
Income before taxes-$8.87M-$7.6M-$8.19M-$8.95M-$10.47M-$12.99M-$9.21M-$9.48M
Income taxes-$18K$328K$57K$83K$0$0$22K$155K
Net income-$8.85M-$7.92M-$8.25M-$9.03M-$10.47M-$12.99M-$9.23M-$9.63M
Net income attributable to common shareholders-$8.85M-$7.92M$8.25B-$16.11M-$9.28M-$8.78M$6.79B-$9.79M
EBITDA-$7.52M-$5.96M-$6.79M-$8.03M-$8.94M-$8.4M-$8.15M-$9.53M
Basic earnings per share-$0.73-$0.85$1.25—-$2.96-$3.54$2.87—
Diluted earnings per share-$0.73-$0.85$1.25—-$2.96-$3.54$2.87—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates

DarioHealth Corp. (DRIO) reported a quarterly loss of $0.44 per share, beating consensus estimates of $0.51 loss, with a 13.73% earnings surprise. Revenues reached $5.31 million, slightly exceeding expectations. However, the stock has plummeted 81.3% year-to-date compared to the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Globus Medical (GMED) Q3 Earnings Top Estimates

Globus Medical reported Q3 2026 earnings of $1.23 per share, beating consensus estimates of $1.20, but revenues of $763.72 million missed expectations by 3.69%. The company maintains a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. The Medical-Instruments industry ranks in the top 43% of Zacks industries.

Benzinga

DarioHealth Reports First Quarter 2026 Financial and Operating Results

DarioHealth (NASDAQ: DRIO) reported Q1 2026 results with second consecutive quarter of sequential revenue growth to $5.6 million, though down year-over-year due to non-recurrence of pharmaceutical customer revenue. The company achieved 21% year-over-year operating expense reduction and improved operating loss by 22% YoY. Channel partnerships now provide access to 116+ million covered lives, with potential expansion to 175+ million. The company maintains $20 million in cash and continues focus on subscription-based recurring revenue and AI-driven engagement programs.

Benzinga

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

DarioHealth Corp. (NASDAQ: DRIO), a digital health company specializing in chronic condition management, announced it will release its Q1 2026 financial results on May 13, 2026 at 8:30 a.m. ET. The company will host a conference call and webcast with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda to discuss results.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 28, 20251-for-20reverse split
Nov 18, 20191-for-20reverse split
Mar 4, 20161-for-18reverse split
Oct 6, 20141-for-5reverse split